To Ensure Accountability, A Whistleblower's Bill Of Rights

The stakes for scientific research integrity have never been higher. Since World War II, a surge of scientific breakthroughs has geometrically increased the profession's benefits and corresponding risks to society. At the same time, federally financed research funding is under the deficit-cutters' microscope. Well-publicized scandals have shaken public confidence that scientific conclusions can be trusted, and that taxpayers are getting their money's worth. Until the perception of integrity is

Written byThomas Devine
| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share

The stakes for scientific research integrity have never been higher. Since World War II, a surge of scientific breakthroughs has geometrically increased the profession's benefits and corresponding risks to society. At the same time, federally financed research funding is under the deficit-cutters' microscope. Well-publicized scandals have shaken public confidence that scientific conclusions can be trusted, and that taxpayers are getting their money's worth. Until the perception of integrity is restored, the flow of federal funding for research is in danger of drying up to a trickle.

Since last July, a congressionally mandated Commission on Research Integrity (CRI) has been holding public hearings to prepare recommendations for Secretary of Health and Human Services Donna Shalala on how to achieve this goal. The only realistic way for universities and research institutes to preempt a disastrous political backlash is by adopting credible structural checks and balances for accountability. In an era of decreasing ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies